Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.240
-0.090 (-6.77%)
At close: Jul 14, 2026, 4:00 PM EDT
1.250
+0.010 (0.81%)
After-hours: Jul 14, 2026, 7:42 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 10 employees as of December 31, 2025. The number of employees increased by 1 or 11.11% compared to the previous year.
Employees
10
Change (1Y)
1
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,843,100
Market Cap
160.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | 1 | 11.11% |
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 164 |
| LENZ Therapeutics | 152 |
| Alector | 103 |
| Caribou Biosciences | 97 |
| PepGen | 59 |
| OnKure Therapeutics | 45 |
| Milestone Pharmaceuticals | 38 |
| Corbus Pharmaceuticals Holdings | 36 |
TLSA News
- 19 days ago - Tiziana Life Sciences doses last patient in intranasal foralumab trial - TheFly
- 19 days ago - Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial - GlobeNewsWire
- 4 weeks ago - Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares - TheFly
- 4 weeks ago - Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - GlobeNewsWire
- 6 weeks ago - Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York - GlobeNewsWire
- 7 weeks ago - Tiziana fully enrolls Phase 2 placebo-controlled MS trial - TheFly
- 7 weeks ago - Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences announces updated intranasal foralumab data - TheFly